The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD
Abstract
OBJECTIVE: Bile acids are regulators of lipid and glucose metabolism, and modulate inflammation in the liver and other tissues. Primary bile acids such as cholic acid and chenodeoxycholic acid (CDCA) are produced in the liver, and converted into secondary bile acids such as deoxycholic acid (DCA) and lithocholic acid by gut microbiota. Here we investigated the possible roles of bile acids in non-alcoholic fatty liver disease (NAFLD) pathogenesis and the impact of the gut microbiome on bile acid signalling in NAFLD. DESIGN: Serum bile acid levels and fibroblast growth factor 19 (FGF19), liver gene expression profiles and gut microbiome compositions were determined in patients with NAFLD, high-fat diet-fed rats and their controls. RESULTS: -taurocholate cotransporting polypeptide and paraoxonase 1, no change in mRNA expression for small heterodimer partner and bile salt export pump, and reduced serum FGF19 were evidence of impaired FXR and fibroblast growth factor receptor 4 (FGFR4)-mediated signalling in NAFLD. Taurine and glycine metabolising bacteria were increased in the gut of patients with NAFLD, reflecting increased secondary bile acid production. Similar changes in liver gene expression and the gut microbiome were observed in high-fat diet-fed rats. CONCLUSIONS: The serum bile acid profile, the hepatic gene expression pattern and the gut microbiome composition consistently support an elevated bile acid production in NAFLD. The increased proportion of FXR antagonistic bile acid explains, at least in part, the suppression of hepatic FXR-mediated and FGFR4-mediated signalling. Our study suggests that future NAFLD intervention may target the components of FXR signalling, including the bile acid converting gut microbiome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Jiao et al. (2018) found that MAFLD patients present elevated primary and secondary bile acids, among which the proportion of DCA is increased and CDCA is decreased.”
From Akkermansia muciniphila alleviates high‐fat‐diet ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids (2023) · cites this paper as Jiao et al. (2018)
In the citing paper
“Additionally, hepatic CYP7A1 expression is enhanced.”
From Akkermansia muciniphila alleviates high‐fat‐diet ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids (2023) · cites this paper as Jiao et al. (2018)
In the citing paper
“With increasing severity of NASH and fibrosis, BA levels tend to increase and the composition of BAs changes”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [91]
In the citing paper
“First, the gut microbiota may affect gastrointestinal transit through its regulation of BA synthesis. The gut microbiota is equipped with enzymes for the production of secondary BAs, which may suppress the FGF19- and FXR-mediated signaling, leading to the induction of CYP7A1 [ 49 , 50 ], and consequently elevated de novo BA synthesis and improved colonic transit.”
From Role of gut microbiota in functional constipation (2021) · cites this paper as [49]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences
Langille, M. G. I., Zaneveld, J., Caporaso, J. G., McDonald, D., Knights, D., Reyes, J. A., Clemente, J. C., Burkepile, D. E., Vega Thurber, R. L., Knight, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2676 · Cited by 9,116
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Research works printed but not linked: 1
- 10.1172/JCI200421025 · DOI
Cited by
Sorted by citations
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166
Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
“Gut dysbiosis contributes to dysregulated bile acid metabolism (687), leading to hyperlipidemia and hyperglycemia (688, 689).”
BackgroundBile acids and the gut microbiota: metabolic interactions and impacts on disease
Collins, S. L., Stine, J. G., Bisanz, J. E., Okafor, C. D., & Patterson, A. D. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00805-x · Cited by 1,214
Gut-liver axis: Pathophysiological concepts and clinical implications
Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843
The gut–liver axis and gut microbiota in health and liver disease
Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737
The Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance
Watt, M. J., Miotto, P. M., De Nardo, W., & Montgomery, M. K. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00034 · Cited by 615
Fleishman, J. S., & Kumar, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01811-6 · Cited by 615
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Fuchs, C. D., & Trauner, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00566-7 · Cited by 490
Molecular physiology of bile acid signaling in health, disease, and aging
Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00502-9 · Cited by 451
Gut–liver axis: barriers and functional circuits
Pabst, O., Hornef, M. W., Schaap, F. G., Cerovic, V., Clavel, T., & Bruns, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00771-6 · Cited by 488
“As DCA has low FXR-activating capability, circulating FGF19 is reduced and FXR-mediated and FGFR4-mediated signalling is suppressed in livers from patients with NAFLD 162,163 .”
BackgroundRole of bile acids in metabolic control
Molinaro, A., Wahlström, A., & Marschall, H.-U. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.11.002 · Cited by 447
Lee, G., You, H. J., Bajaj, J. S., Joo, S. K., Yu, J., Park, S., Kang, H., Park, J. H., Kim, J. H., Lee, D. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18754-5 · Cited by 395
Chu, H., Duan, Y., Yang, L., & Schnabl, B. (2019) · Gut · doi:10.1136/gutjnl-2018-316307 · Cited by 354
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 387
“FXR signaling was inhibited in patients with NAFLD and rats fed an HFD, probably due to deoxycholic acid (DCA), an FXR antagonistic secondary BA, increased while the agonistic CDCA was decreased.(193) In the light of the potential hepatotoxic effects of BAs and BAs-induced FXR signaling to regulate insulin sensitivity…”
BackgroundGut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway
Nie, Q., Luo, X., Wang, K., Ding, Y., Jia, S., Zhao, Q., Li, M., Zhang, J., Zhuo, Y., Lin, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.034 · Cited by 356
Liu, N.-N., Jiao, N., Tan, J.-C., Wang, Z., Wu, D., Wang, A.-J., Chen, J., Tao, L., Zhou, C., Fang, W., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01030-7 · Cited by 306
Self-citationLean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation
Chen, F., Esmaili, S., Rogers, G. B., Bugianesi, E., Petta, S., Marchesini, G., Bayoumi, A., Metwally, M., Azardaryany, M. K., Coulter, S., et al. (2019) · Hepatology · doi:10.1002/hep.30908 · Cited by 338
“FXR dysregulation has been implicated in the pathogenesis of NAFLD; therefore, we were interested to determine if differential effects are observed in lean versus nonlean NAFLD.(20,21) To examine for this, serum FGF19, a surrogate marker of FXR activity, was measured.”
BackgroundSen, P., Qadri, S. U., Luukkonen, P. K., Ragnarsdóttir, O., McGlinchey, A. J., Jäntti, S. E., Juuti, A., Arola, J. T., Schlezinger, J. J., Webster, T. F., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.039 · Cited by 299
Jiao, N., Baker, S. S., Nugent, C. A., Tsompana, M., Cai, L., Wang, Y., Buck, M. J., Genco, R. J., Baker, R. D., Zhu, R., et al. (2018) · Physiological Genomics · doi:10.1152/physiolgenomics.00114.2017 · Cited by 290
Self-citationIdentification of microbial markers across populations in early detection of colorectal cancer
Wu, Y., Jiao, N., Zhu, R., Zhang, Y., Wu, D., Wang, A.-J., Fang, S., Tao, L., Li, Y., Cheng, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23265-y · Cited by 266
“Gut microbiome is a novel stool-based non-invasive biomarker for metabolic diseases and cancers(5, 6).”
BackgroundSelf-citationNonalcoholic Fatty Liver Disease
Zhao, Y.-C., Zhao, G., Chen, Z., She, Z., Cai, J., & Li, H. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13419 · Cited by 244
“The liver, as a predominant metabolic and endocrine organ, can release various metabolites, including glucose, VLDL, and bile acids (BAs), which can transduce metabolic signals, resulting in systemic IR.31 Accumulating experimental and clinical evidence has highlighted a close and causal relationship between NAFLD and…”
InfluentialBile acid metabolism and signalling in liver disease
Fuchs, C. D., Simbrunner, B., Baumgartner, M., Campbell, C., Reiberger, T., & Trauner, M. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.032 · Cited by 265
Microbiota and Fatty Liver Disease—the Known, the Unknown, and the Future
Lang, S., & Schnabl, B. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.07.007 · Cited by 244
“Liver tissues from patients with NASH have increased expression of genes involved in bile acid synthesis and reduced expression of FGF19, compared with healthy controls (Jiao et al., 2018).”
BackgroundTan, X., Liu, Y., Long, J., Chen, S., Liao, G., Wu, S., Li, C., Wang, L., Ling, W., & Zhu, H. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900257 · Cited by 236
Intestinal Bacteria Interplay With Bile and Cholesterol Metabolism: Implications on Host Physiology
Molinero, N., Ruíz, L., Sánchez, B., Margollés, A., & Delgado, S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00185 · Cited by 233
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Association of metabolic dysfunction-associated fatty liver disease with kidney disease
Wang, T.-Y., Wang, R.-F., Bu, Z.-Y., Targher, G., Byrne, C. D., Sun, D.-Q., & Zheng, M.-H. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00519-y · Cited by 226
Immunological mechanisms and therapeutic targets of fatty liver diseases
Wang, H., Mehal, W. Z., Nagy, L. E., & Rotman, Y. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00579-3 · Cited by 234
Intestinal Barrier and Permeability in Health, Obesity and NAFLD
Portincasa, P., Bonfrate, L., Khalil, M., Angelis, M. D., Calabrese, F. M., D’Amato, M., Wang, D. Q. ‐., & Ciaula, A. D. (2021) · Biomedicines · doi:10.3390/biomedicines10010083 · Cited by 219
“[624] demonstrated that NAFLD was associated with increased serum concentrations of primary and secondary BA.”
BackgroundFang, J., Yu, C.-H., Li, X.-J., Yao, J., Fang, Z., Yoon, S., & Wenying, Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.997018 · Cited by 226
“” Escherichia, Bilophila and Rhodobacter involved in BAs-mediating taurine and glycine metabolism were significantly increased in the faeces of NASH patients (Jiao et al., 2018).”
BackgroundInfluentialYe, J., Lv, L., Wu, W., Li, Y., Shi, D., Fang, D., Guo, F., Jiang, H., Ren, Y., Ye, W., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01967 · Cited by 211
“The liver–gut axis plays a pivotal role in NAFLD pathogenesis and progression (Jiao et al., 2017; Zhu et al., 2017).”
BackgroundGuan, B., Tong, J., Hao, H., Yang, Z., Chen, K., Xu, H., & Wang, A. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.011 · Cited by 215
Sun, L., Pang, Y., Wang, X., Wu, Q., Liu, H., Liu, B., Liu, C., Ye, M., Kong, W., & Jiang, C. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.02.004 · Cited by 207
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Animal models of NAFLD from a hepatologist's point of view
Jahn, D., Kircher, S., Hermanns, H. M., & Geier, A. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.06.023 · Cited by 201
Sharpton, S. R., Schnabl, B., Knight, R., & Loomba, R. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.010 · Cited by 194
“Serum concentrations of primary and secondary bile acids are increased in individuals with NAFLD (Jiao et al., 2018).”
BackgroundBile acid signaling in the regulation of whole body metabolic and immunological homeostasis
Jia, W. P., Li, Y., Cheung, K. C.-P., & Zheng, X. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2353-0 · Cited by 207
“Dysregulation of BA-liver metabolic interactions is linked to the development of non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) (Clifford et al., 2021; Jiao et al., 2018; Yoshimoto et al., 2013).”
Update on FXR Biology: Promising Therapeutic Target?
Han, C. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072069 · Cited by 194
“In the NAFLD condition, the proportion of BAs antagonizing the FXR activity increased, which may account for, at least in part, the reduction of FGF15/19 and FGFR4-mediated signaling [117].”
BackgroundRole of gut microbiota in functional constipation
Zhang, S., Wang, R., Li, D., Zhao, L., & Zhu, L. (2021) · Gastroenterology Report · doi:10.1093/gastro/goab035 · Cited by 175
“CYP7A1 [49, 50], and consequently elevated de novo BA synthesis”
BackgroundSelf-citationLi, M., Wang, S., Li, Y., Zhao, M., Kuang, J., Liang, D., Wang, J., Wei, M., Rajani, C., Ma, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29589-7 · Cited by 175
Wang, S., Sheng, F., Zou, L., Xiao, J., & Li, P. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.06.001 · Cited by 182
“Disorders of lipid metabolism usually result from abnormal BA metabolisms, and hepatic lipid accumulation is one of important inducers of NAFLD [8,58].”
BackgroundThe acidic pathway of bile acid synthesis: Not just an alternative pathway
Pandak, W. M., & Kakiyama, G. (2019) · Liver Research · doi:10.1016/j.livres.2019.05.001 · Cited by 181
Sharpton, S. R., Ajmera, V. H., & Loomba, R. S. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.08.065 · Cited by 177
“Adults with NAFLD have elevated total serum bile acids and alterations in the ratio of secondary to primary bile acids,(72) which was subsequently found to be associated with a shift in abundance of gut microbes associated with bile acid deconjugation.(73) Moreover, fecal bile acid composition distinguishes adults wit…”
Ciaula, A. D., Baj, J., Garruti, G., Celano, G., Angelis, M. D., Wang, H. H., Palo, D. M. D., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082648 · Cited by 166
Gut microbiota derived bile acid metabolites maintain the homeostasis of gut and systemic immunity
Su, L., Gao, Y., & Yang, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127743 · Cited by 174
“Dysregulation of BA metabolism was linked to steatosis, inflammation, and fibrosis in patients with NAFLD (137).”
BackgroundInfluentialObesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
The gut vascular barrier: a new player in the gut–liver–brain axis
Brescia, P., & Rescigno, M. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.06.007 · Cited by 163
Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus
Wu, J., Yang, K., Fan, H., Wei, M., & Xiong, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1114424 · Cited by 176
“Frontiers in Endocrinology 04 reduces bile acid synthesis (69, 70).”
BackgroundRole of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?
Fukui, H. (2019) · Diseases · doi:10.3390/diseases7040058 · Cited by 159
Gut microbiome and bile acids in obesity-related diseases
Li, R., Andreu‐Sánchez, S., Kuipers, F., & Fu, J. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101493 · Cited by 154
Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD)
Syed‐Abdul, M. M. (2023) · Metabolites · doi:10.3390/metabo14010012 · Cited by 166
Bile Acids, Intestinal Barrier Dysfunction, and Related Diseases
Shi, L., Jin, L., & Huang, W. (2023) · Cells · doi:10.3390/cells12141888 · Cited by 155
Zhong, J., He, X., Gao, X., Liu, Q., Zhao, Y., Hong, Y., Zhu, W., Yan, J., Li, Y., Li, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41061-8 · Cited by 139
Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression
Gottlieb, A., & Canbay, A. E. (2019) · Cells · doi:10.3390/cells8111358 · Cited by 138
“Additionally, taurine and glycine metabolizing bacteria were increased in the gut of NAFLD patients, which reflects an increased secondary BA production [46].”
BackgroundCaussy, C., Hsu, C. L., Singh, S., Bassirian, S., Kolar, J., Faulkner, C., Sinha, N., Bettencourt, R., Gara, N., Valasek, M. A., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15035 · Cited by 134
“Likewise, a comprehensive study performed by Jiao et al have shown that circulating bile acid profile, hepatic gene expression pattern and gut microbiome composition in NASH are in favour of an increased proportion of FXR antagonist bile acids which could at least partially explain a reduced FXR signalling in NASH.(23…”
BackgroundJuárez‐Fernández, M., Porras, D., Petrov, P., Román-Sagüillo, S., García‐Mediavilla, M. V., Soluyanova, P., Martínez‐Flórez, S., González‐Gallego, J., Nistal, E., Jover, R., et al. (2021) · Antioxidants · doi:10.3390/antiox10122001 · Cited by 133
“In fact, our research group has previously identified an association between Clostridium genus and an altered BA fecal metabolome [24], whereas Streptococcus has been linked with NASH or even cirrhosis and hepatocarcinoma development [40,44].”
BackgroundInfluentialAltered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC
Sydor, S., Best, J., Messerschmidt, I., Manka, P., Vilchez-Vargas, R., Brodesser, S., Lucas, C., Wegehaupt, A., Wenning, C., Aßmuth, S., et al. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000131 · Cited by 127
“Here, an increase in BA levels and an altered composition of the BA pool with an increase in secondary conjugated BA was observed (24).”
BackgroundDing, Y., Yanagi, K., Cheng, C., Alaniz, R. C., Lee, K., & Jayaraman, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.029 · Cited by 125
Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
Kim, H.-M., Lee, D. S., An, T. H., Park, H., Kim, W. K., Bae, K., & Oh, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094495 · Cited by 133
“In NASH, the levels of serum FGF19, fibroblast growth factor receptor 4 (FGFR4), and bile acids are significantly increased, and results in impaired FXR and FGFR4-mediated signaling [317,318].”
BackgroundWu, W., Kaicen, W., Bian, X., Yang, L., Ding, S., Li, Y., Li, S., Zhuge, A., & Li, L. (2023) · Microbial Biotechnology · doi:10.1111/1751-7915.14293 · Cited by 129
Wei, W., Jiang, W., Tian, Z., Wu, H., Ning, H., Yan, G., Zhang, Z., Li, Z., Dong, F., Sun, Y., et al. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.01.031 · Cited by 125
Giuffrè, M., Campigotto, M., Campisciano, G., Comar, M., & Crocè, L. S. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00161.2019 · Cited by 122
Role of bile acids in inflammatory liver diseases
Evangelakos, I., Heeren, J., Verkade, E., & Kuipers, F. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00869-6 · Cited by 121
Guo, W. Y., Zhu, S., Li, S., Feng, Y., Wu, H., & Zeng, M. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.05.067 · Cited by 119
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
Jiao, T., Ma, Y., Guo, X., Ye, Y., & Xie, C. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00880-z · Cited by 122
“In the classical pathway, cholesterol is first hydroxylated by cholesterol 7α-hydroxylase (CYP7A1) to produce 7α-hydroxycholesterol.”
BackgroundInfluentialFibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives
Somm, E., & Jornayvaz, F. R. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00134 · Cited by 124
Hepatokines and adipokines in NASH-related hepatocellular carcinoma
Kücükoglu, Ö., Sowa, J., Mazzolini, G. D., Syn, W., & Canbay, A. E. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.10.030 · Cited by 114
Intestinal flora imbalance affects bile acid metabolism and is associated with gallstone formation
Wang, Q., Hao, C., Yao, W., Zhu, D., Lu, H., Li, L., Ma, B., Sun, B., Xue, D., & Zhang, W. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01195-1 · Cited by 112
“Under physiological concentrations, bile acids, especially hydrophilic secondary bile acids, play a role in the assembly of NLRP3 inflammasomes as negative regulators, and this effect requires functional FXR [36, 37].”
BackgroundInfluentialYang, J., Chen, H., Nie, Q., Huang, X., & Nie, S. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.08.007 · Cited by 109
Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia
Chen, Z., Liu, J., Zhou, F., Li, H., Zhang, X., She, Z., Lu, Z., Cai, J., & Li, H. (2021) · Circulation Research · doi:10.1161/circresaha.121.319059 · Cited by 108
Bile acids contribute to the development of non-alcoholic steatohepatitis in mice
Gillard, J., Clerbaux, L., Nachit, M., Sempoux, C. L., Staels, B., Bindels, L. B., Tailleux, A., & Leclercq, I. A. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100387 · Cited by 111
Li, X., Zhu, L., Wang, B., Yuan, M., & Zhu, R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00855 · Cited by 103
“…combination of traditional transcriptomics approaches with emerging technologies, including proteomics (Ordureau et al., 2014), metabolomics (Shah et al., 2012), and metagenomics (Jiao et al., 2017), will offer unprecedented opportunities to precisely elucidating and dissecting fibrosis mechanisms.”
BackgroundSelf-citationTokuhara, D. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.700058 · Cited by 106
“In children with NAFLD, serum concentrations of primary and secondary BAs and intestinal secondary BA-producing bacteria are increased, whereas hepatic FXR-mediated and FGF receptor 4-mediated BA signaling is suppressed (108).”
BackgroundLau, H. C.-H., Zhang, X., & Yu, J. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01089-1 · Cited by 126
Microbial Metabolites: Critical Regulators in NAFLD
Dai, X., Hou, H., Zhang, W., Liu, T., Li, Y., Wang, S., Wang, B., & Cao, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.567654 · Cited by 103
Byrne, C. D., Armandi, A., Pellegrinelli, V., Vidal‐Puig, A., & Bugianesi, E. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01045-z · Cited by 113
Hu, W., Gao, W., Liu, Z., Fang, Z., Wang, H., Zhao, J., Zhang, H., Lu, W., & Chen, W. (2022) · Nutrients · doi:10.3390/nu14142945 · Cited by 104
“Additionally, bile acid metabolism by intestinal flora activates the nuclear bile acid receptor farnesoid X receptor (FXR) signaling, thereby affecting the progression of NAFLD [11].”
BackgroundSun, J., Fan, J., Li, T., Yan, X., & Jiang, Y. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c04817 · Cited by 100
Microbial metabolites in non-alcoholic fatty liver disease
Zhou, D., & Fan, J. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i17.2019 · Cited by 96
Chen, L., van den Munckhof, I., Schraa, K., ter Horst, R., Koehorst, M., van Faassen, M. H. J. R., van der Ley, C., Doestzada, M., Zhernakova, D. V., Kurilshikov, A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108212 · Cited by 92
Zhu, X., Cai, J., Wang, Y., Liu, X., Chen, X., Wang, H., Wu, Z., Bao, W., Fan, H., & Wu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316733 · Cited by 96
“Additionally, bile acid metabolism by gut microbiota activates the nuclear bile acid receptor farnesoid X receptor signaling, thereby affecting the progression of NAFLD [18].”
BackgroundYe, J., Li, Y., Wu, W., Shi, D., Fang, D., Yang, L.-Y., Bian, X., Wu, J., Wáng, Q., Jiang, X., et al. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i23.2468 · Cited by 89
Alferink, L. J. M., Radjabzadeh, D., Erler, N. S., Vojinović, D., Medina‐Gómez, C., Uitterlinden, A. G., de Knegt, R. J., Amin, N., Ikram, M. A., Janssen, H. L. A., et al. (2020) · Hepatology · doi:10.1002/hep.31417 · Cited by 87
The functions of gut microbiota-mediated bile acid metabolism in intestinal immunity
He, Y., Shaoyong, W., Chen, Y., Li, M., Gan, Y., Sun, L., Liu, Y., Wang, Y., & Jin, M. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.05.015 · Cited by 107
“Additionally, patients with NAFLD exhibited higher serum levels of PBAs and SBAs [133].”
Recent advances on FXR-targeting therapeutics
Panzitt, K., Zollner, G., Marschall, H., & Wagner, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111678 · Cited by 88
Xu, W., Cui, C., Cui, C., Chen, Z., Zhang, H., Cui, Q., Xu, G., Fan, J., Han, Y., Tang, L., et al. (2022) · Hepatology · doi:10.1002/hep.32577 · Cited by 86
“Interestingly, serum FXR antagonistic bile acids lithocholic acid and deoxycholic acid were increased (similar to patients with NAFLD[19]), whereas tauro- β- muricholic acid (increased by FXR agonist[20]) was decreased in CSELKO mice (Figure S12A,B).”
Xu, J., Xie, S., Chi, S., Zhang, S., Cao, J., & Tan, B. (2022) · Food & Function · doi:10.1039/d1fo04085e · Cited by 84
Zhang, X., Lau, H. C.-H., & Yu, J. Q. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100018 · Cited by 100
Bile Acids, Their Receptors, and the Gut Microbiota
Poland, J. C., & Flynn, C. R. (2021) · Physiology · doi:10.1152/physiol.00028.2020 · Cited by 93
Metabolic Reprogramming of HCC: A New Microenvironment for Immune Responses
Foglia, B., Beltrà, M., Sutti, S., & Cannito, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087463 · Cited by 82
Chávez‐Talavera, O., Haas, J. T., Grzych, G., Tailleux, A., & Staels, B. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000597 · Cited by 83
Adams, L. A., Wang, Z., Liddle, C., Melton, P. E., Ariff, A., Chandraratna, H. S., Tan, J. T. H., Ching, H. L., Coulter, S., de Boer, B., et al. (2020) · Liver International · doi:10.1111/liv.14453 · Cited by 79
Radun, R., & Trauner, M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1731707 · Cited by 83
Pan, X., Wen, S. W., Kaminga, A. C., & Liu, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-65051-8 · Cited by 80
Liang, H., Jiang, F., Cheng, R., Luo, Y., Wang, J., Luo, Z., Li, M., Shen, X. P., & He, F. (2020) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.20-0094 · Cited by 78
Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD
Jiang, X., Zheng, J., Zhang, S., Wang, B., Wu, C., & Guo, X. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00361 · Cited by 80
“In addition, secondary BAs were increased in the intestine of patients with NAFLD via enhancing the metabolism of taurine and glycine (83).”
BackgroundChronic lead exposure induces fatty liver disease associated with the variations of gut microbiota
Wan, H., Wang, Y., Zhang, H., Zhang, K., Chen, Y., Chen, C., Zhang, W., Xia, F., Wang, N., & Lu, Y. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.113257 · Cited by 77
The ameliorative effect of probiotics on diet-induced lipid metabolism disorders: A review
Wang, Y., Ai, Z., Xing, X., Fan, Y., Zhang, Y., Nan, B., Li, X., Wang, Y., & Liu, J. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2132377 · Cited by 81
“Importantly, recent studies have shown that the concentration of BAs was increased of patients with lipid metabolism disorders induced by HFD (Jiao et al. 2018).”
BackgroundFang, H., Lacerda, R. R. E., Barra, N. G., Zada, D. K., Robin, N., Mehra, A., & Schertzer, J. D. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae025 · Cited by 82
“Diet-induced obese mice have higher levels of bile salt hydrolases, a class of bacterial enzymes involved in the conversion of primary to secondary BAs (92).”
Influential
Metadata
- Authors
- Jiao, N., Baker, S. S., Chapa-Rodriguez, A., Liu, W., Nugent, C. A., Tsompana, M., Mastrandrea, L., Buck, M. J., Baker, R. D., Genco, R. J., Zhu, R., & Zhu, L.
- Affiliations
- Tongji University (CN)
- University at Buffalo, State University of New York (US)
- Department of Pediatrics, Digestive Diseases and Nutrition Center, The State University of New York at Buffalo, Buffalo, New York, USA
- Corresponding author
- Baker, Susan S
- Zhu, Lixin
- ORCID
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2017-08-03
- Volume
- 67
- Issue
- 10
- Pages
- 1881-1891
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2605955022
- Cited by
- 737
- References
- 50
- Citations by year
- 2026: 81 · 2025: 112 · 2024: 128 · 2023: 105 · 2022: 93 · 2021: 83 · 2020: 68 · 2019: 44 · 2018: 17 · 2017: 4
- FWCI
- 15.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gut (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- GEM Community of Excellence, the University at Buffalo
- the University at Buffalo Departmental Start-Up Fund
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- the Peter and Tommy Fund, Inc., Buffalo, NY
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- non-alcoholic fatty liver disease, bile acids, bile acid signaling, farnesoid X receptor, FGFR4, FGF19, gut microbiota, secondary bile acids, deoxycholic acid, lithocholic acid, taurine metabolism, hepatic gene expression, high-fat diet
- MeSH terms
- Gastrointestinal Microbiome, Receptor, Farnesoid X-Activated, Animals, Bile Acids and Salts, Cholesterol 7-alpha-Hydroxylase, Female, Fibroblast Growth Factors, Humans, Male, Middle Aged, Signal Transduction, Receptors, Cytoplasmic and Nuclear, Gene Expression Profiling, Rats, Diet, High-Fat, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
